HomeMarketWhy Arcus Bio...

Why Arcus Biosciences Inc. (NYSE:RCUS) Stock up 2.29% in Last Week?

BofA Securities raised the price target for the Arcus Biosciences Inc. (NYSE:RCUS) stock to “a Neutral”. The rating was released on November 18, 2022, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $57. The stock was initiated by Berenberg, who disclosed in a research note on November 24, 2020, to Buy and set the price objective to $50.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Arcus Biosciences Inc. (NYSE:RCUS) dipped 0.00% to close Thursday’s market session at $16.96, lower as compared to yesterday’s close. The stock price fluctuated between $16.38 and $17.19 throughout the trading session with the volume trading being 759665 shares, which represented a significant variation when compared to the three months average volume of 1.17 million shares. The firm’s stock price fluctuated 2.29% within the last five trades and -14.08% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -34.74% in the last 6 months and -48.76% was subtracted to its value over the previous 3 months. RCUS stock is trading at a margin of -6.08%, -13.41% and -31.09% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


As of the close of trading, RCUS deals in the Healthcare domain. The stock is trading -57.33 percent below its 52-week high and 8.03 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -49.3. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Arcus Biosciences Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $1.24 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 11.08 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.88, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.90 percent of Arcus Biosciences Inc. shares are owned by insiders, and 74.30 percent are held by financial institutions. Jarrett Jennifer, the Chief Operating Officer at Arcus Biosciences Inc. (RCUS) has sold 1,600 shares of firm on Jan 27 at a price of $23.52 against the total amount of $37632.0. In another inside trade, Jarrett Jennifer, Chief Operating Officer of Arcus Biosciences Inc. (NYSE:RCUS) sold 300 shares of the firm on Jan 26 for a total worth of $7068.0 at a price of $23.56. An inside trade which took place on Dec 16, Chief Operating Officer of Arcus Biosciences Inc. Jarrett Jennifer sold 16,482 shares of firm against total price of $0.51 million at the cost of $30.75 per share.



Please enter your comment!
Please enter your name here

Recent Post